Digitalis Ventures is a venture capital firm that invests in solutions to complex problems in human and animal health. They partner with entrepreneurs, inventors, and scientists across all stages of venture investing, and their investments span the full continuum of the healthcare ecosystem.

Digitalis Ventures

Hankscraft Inc. is a contract manufacturer that produces a variety of products across multiple industries, including consumer products, pet care, HVAC, home appliances, and motors. The company offers services from project management to manufacturing.

Hankscraft Inc.

Happy Dog Food provides fresh, natural, and healthy food options for dogs, claiming to improve their overall wellness and lifespan. The company promotes meals made from human-grade ingredients that owners can prepare at home.

Happy Dog Food

Lucidity LLC is a healthcare specialist advisory practice that applies business experience and industry insights for investors and executives. It focuses on delivering meaningful business change and transformation in healthcare and life sciences companies.

Lucidity LLC

Digitalis Ventures is a venture capital firm that invests in solutions to complex problems in human and animal health. Digitalis partners with entrepreneurs, scientists, and inventors across all stages of venture investing. The firm comprises technical professionals with deep industry experience and networks in diverse areas related to human and animal health. Through domain expertise and a dedication to the entrepreneurial process, Digitalis is deeply committed to helping their portfolio companies scale their impact on the world.

Good Therapeutics

Misti Ushio, Managing Partner at Digitalis Ventures, will be speaking alongside Advanced Research Projects Agency for Health (ARPA-H) Director Renee Wegrzyn & Program Manager Darshak Sanghavi as part of the ARPA-H Fireside Chat, moderated by Ipsita Smolinski, at the J.P Morgan Healthcare Conference on January 7th at 7am PT. We hope to see you there!

As is now a tradition, our last missive of the year is an opportunity for us to reflect on the topics we covered earlier in the year in our Notes on Engineering Health and see if any updates are in order. The whole team at Digitalis Ventures wishes you a happy, healthy, and peaceful New Year.

Pets vs. Pests: Many of us remember the days when bringing beloved pets into our homes brought fleas, ticks, parasites and disease risks with them. Read why today there is an urgent need for new, safe, effective treatments to keep threats to animal and human health at bay. 

PLUS: AI for Goose beak recognition, cats as amazing hunters, cats that fetch, gender equality in the benefits of dog hugs, and the effects of neutering on animal lifespan.

https://lnkd.in/egtbJUx2

#pets #pethealth #animalhealth #animallovers

We're thrilled that our partners at Terray Therapeutics have announced a multi-target collaboration agreement with Bristol Myers Squibb to discover and develop small molecule therapeutics.

Notes on How We Drug The Brain. The late neurologist Oliver Sacks had his fair share of experience with experiments on chemical compounds altering brain functions. He wrote beautifully in books and articles about how he experimented on himself both to relieve pain and to explore unvisited corners of his self. He was a keen observer of how mental diseases work and what is available to treat them. How did we get to produce such neuro-active compounds? Are the nervous system and the brain like any other organs? Where is neuropharmacology going?

ALSO:
The science of Zoom fatigue, the immune response of exercise, a cause of itching, neurons controlling ingestion in our taste buds, and a neurochemical brain wave that controls motivation.

#neuropharmacology #neurology #psychedelics #zoomfatigue #exercise

A few months ago, we wrote about the historical accident that is the current employer-sponsored healthcare insurance system in the US. Today, we explore another idiosyncratic feature of the American healthcare system, its payer system. What is a payer? How does it interact with other actors, like providers and pharmacies? How is it evolving?

PLUS: a new map of the brain at unprecedented resolution, the gene for good parenting (in mice), social determinants of health and child development, a window into the heart, and why so many carrots are orange.

#payers #healthcare #healthinsurance #singlepayer #multipayer

The social contract around big data and information technology is broken.

The combination of years of “Big Data” hype and obviously flawed inferences, of overpromising and under-delivering, has led to pervasive online tracking and a miasma of distrust.  It is simultaneously too difficult to deploy novel consumer-facing information technology and avoid the sale or at least use of personal information. 

Population data matter even if the promises of big data were vastly overblown. In our reaction to over a decade of hype, we should act prudently and not cripple the ability of researchers, government, and, yes, businesses to better understand the vast diversity of mankind. We must focus on the harms of panopticon and tracking, while allowing large datasets to grow safely, secure in the knowledge that there is no oracle of “big data.” 

The map is not the territory—all the more reason to build better maps.

https://lnkd.in/eE7p9C4j

#data #datascience #machinelearning

Thanks Robert Lavine & Global Corporate Venturing for an insightful dive into Companion Fund II with our Ben Jacobs. Fueled by Mars, we are excited to work with founders who have great ideas for improving animal health.

“The first fund was $100m, and this one being $300m really opens up the aperture for us to enter companies at growth stage and support the companies we’re already in through their growth stages,” – Ben Jacobs

#petcare #animalhealth #veterinarians #investing #founders

Drew Taylor | Cynthia Cole | Geoffrey Smith | Misti Ushio

Announcing the inaugural issue of Notes on Animal Health, a newsletter highlighting the ways we are tackling the most important problems and opportunities to provide for the health and welfare of our pets. Through our Companion Funds, we invest in solutions across the pet health ecosystem. We invite you to be in touch with your ideas for potential solutions in petcare so we can work together to deliver better health to all. Cynthia Cole / Geoffrey Smith / Ben Jacobs / Drew Taylor / Misti Ushio

#pets #petcare #petdiagnostics #animalhealth #veterinarians #investing

Metric
Company Name	Digitalis Ventures	Hankscraft Inc.	Happy Dog Food	Lucidity LLC
Symbol
MSH ID	COM:DIGITALISVENTURES	COM:HANKSCRAFT	COM:HAPPYDOGFOOD	COM:LUCIDITYLLC
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare and Life Sciences	Commercial & Professional Services	Consumer Goods	Commercial & Professional Services
Industry	Venture Capital	Manufacturing	Pet Food	Healthcare & Health Services
Country	US	US	US	US
Stage
Employee Count	19		1
Website	digitalisventures.com	hankscraft.com	happydogfood.com	lucidityllc.com
LinkedIn	digitalis-ventures			lucidity-llc1
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic			1.39K
Web Traffic Growth			4.65
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:DIGITALISVENTURES

Digitalis Ventures

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue